George J D, Price C J, Kimmel C A, Marr M C
Fundam Appl Toxicol. 1987 Jul;9(1):173-81. doi: 10.1016/0272-0590(87)90164-3.
Triethylene glycol dimethyl ether (triEGdiME) is structurally related to several compounds which produce reproductive and developmental toxicity, including teratogenicity in laboratory animals. In the present study, triEGdiME (0, 250, 500, or 1000 mg/kg/day) was administered by gavage to timed-pregnant CD-1 mice during major organogenesis (Gestational Days (gd) 6-15). Maternal clinical status was monitored daily during treatment. At sacrifice (gd 17), confirmed-pregnant females (26-28 per group) were evaluated for clinical status and gestational outcome; each live fetus was examined for external, visceral, and skeletal malformations. No maternal death or morbidity was observed. Clinical signs of toxicity including piloerection were minor. Maternal weight gain during treatment, gestation, and maternal weight gain during gestation corrected for gravid uterine weight were not affected. Gravid uterine weight decreased in a dose-related manner, indicating compromised pregnancy status. Relative maternal liver weight (% body wt) was significantly increased over controls at doses greater than or equal to 500 and 1000 mg/kg/day. Average fetal body weight per litter was significantly reduced at doses greater than or equal to 500 mg/kg/day. The percentage malformed live fetuses per litter (0.3, 0, 0.8, and 11.1%) was significantly increased at 1000 mg/kg/day. Major malformations affected primarily the development of the neural tube, craniofacial structures, and the axial skeleton. In summary, oral administration of triEGdiME during major organogenesis produced only marginal signs of altered maternal status, as evidenced by an increase in maternal liver weight, and caused selective adverse effects upon fetal growth and morphological development at doses greater than or equal to 500 mg/kg/day.
三甘醇二甲醚(triEGdiME)在结构上与几种产生生殖和发育毒性的化合物相关,包括在实验动物中具有致畸性。在本研究中,在主要器官形成期(妊娠第6 - 15天),将triEGdiME(0、250、500或1000 mg/kg/天)经口灌胃给予定时受孕的CD - 1小鼠。在治疗期间每天监测母鼠的临床状态。在处死时(妊娠第17天),对确认怀孕的雌性小鼠(每组26 - 28只)进行临床状态和妊娠结局评估;检查每只活胎仔的外部、内脏和骨骼畸形情况。未观察到母鼠死亡或发病情况。包括竖毛在内的毒性临床体征较轻。治疗期间的母鼠体重增加、妊娠期母鼠体重增加以及校正妊娠子宫重量后的妊娠期母鼠体重增加均未受影响。妊娠子宫重量呈剂量相关下降,表明妊娠状态受损。在剂量大于或等于500和1000 mg/kg/天时,相对母鼠肝脏重量(%体重)显著高于对照组。在剂量大于或等于500 mg/kg/天时,每窝平均胎仔体重显著降低。在1000 mg/kg/天时,每窝畸形活胎仔的百分比(0.3%、0%、0.8%和11.1%)显著增加。主要畸形主要影响神经管、颅面结构和轴向骨骼的发育。总之,在主要器官形成期经口给予triEGdiME仅产生轻微的母鼠状态改变迹象,如母鼠肝脏重量增加所证明的那样,并在剂量大于或等于500 mg/kg/天时对胎儿生长和形态发育产生选择性不良影响。